BACKGROUND: Antimicrobial resistance in invasive infections is driven mainly by human antimicrobial consumption. Limited cross-national comparative evidence exists about variation in antimicrobial consumption and effect on resistance. METHODS: We examined the relationship between national community antimicrobial consumption rates (2013) and national hospital antimicrobial resistance rates (2014) across 29 countries in the European Economic Area (EEA). Consumption rates were obtained from the European Surveillance of Antimicrobial Consumption Network (ESAC-Net). Resistance data were obtained from the European Antimicrobial Resistance Surveillance Network (EARS-Net), based on 196480 invasive isolates in 2014. RESULTS: Data availability and consistency were good. Some countries did not report figures for each strain of resistant bacteria. National antimicrobial consumption rates (2013) varied from ≤ 13 DDD (Estonia, the Netherlands and Sweden) to ≥ 30 DDD (France, Greece and Romania) per 1000 inhabitants per day. National antimicrobial resistance rates (hospital isolates, 15 species) also varied from <6.1% (Finland, Iceland and Sweden) to > 37.2% (Bulgaria, Greece, Romania and Slovakia). National antimicrobial consumption rates (2013) showed strong to moderate correlation with national hospital antimicrobial resistance rates (2014) in 19 strains of bacteria (r = 0.84 to r = 0.39). Some countries defied the trend with high consumption and low resistance (France, Belgium and Luxembourg) or low consumption and high resistance (Bulgaria, Hungary and Latvia). CONCLUSIONS: We found associations between national community antimicrobial consumption and national hospital antimicrobial resistance across a wide range of bacteria. These associations were not uniform. Different mechanisms may drive resistance in hospital-based invasive infections. Future research on international variations in antimicrobial resistance should consider environmental factors, agricultural use, vaccination policies and prescribing quality.
BACKGROUND: Antimicrobial resistance in invasive infections is driven mainly by human antimicrobial consumption. Limited cross-national comparative evidence exists about variation in antimicrobial consumption and effect on resistance. METHODS: We examined the relationship between national community antimicrobial consumption rates (2013) and national hospital antimicrobial resistance rates (2014) across 29 countries in the European Economic Area (EEA). Consumption rates were obtained from the European Surveillance of Antimicrobial Consumption Network (ESAC-Net). Resistance data were obtained from the European Antimicrobial Resistance Surveillance Network (EARS-Net), based on 196480 invasive isolates in 2014. RESULTS: Data availability and consistency were good. Some countries did not report figures for each strain of resistant bacteria. National antimicrobial consumption rates (2013) varied from ≤ 13 DDD (Estonia, the Netherlands and Sweden) to ≥ 30 DDD (France, Greece and Romania) per 1000 inhabitants per day. National antimicrobial resistance rates (hospital isolates, 15 species) also varied from <6.1% (Finland, Iceland and Sweden) to > 37.2% (Bulgaria, Greece, Romania and Slovakia). National antimicrobial consumption rates (2013) showed strong to moderate correlation with national hospital antimicrobial resistance rates (2014) in 19 strains of bacteria (r = 0.84 to r = 0.39). Some countries defied the trend with high consumption and low resistance (France, Belgium and Luxembourg) or low consumption and high resistance (Bulgaria, Hungary and Latvia). CONCLUSIONS: We found associations between national community antimicrobial consumption and national hospital antimicrobial resistance across a wide range of bacteria. These associations were not uniform. Different mechanisms may drive resistance in hospital-based invasive infections. Future research on international variations in antimicrobial resistance should consider environmental factors, agricultural use, vaccination policies and prescribing quality.
Authors: Boun Kim Tan; Emmanuel Vivier; Karim Ait Bouziad; Jean-Ralph Zahar; Christian Pommier; Laurence Parmeland; Caroline Pariset; Pauline Misslin; Catherine Haond; Philippe Poirié; Laura Temime; Mounia N Hocine Journal: Intensive Care Med Date: 2018-02-02 Impact factor: 17.440
Authors: Martina Barchitta; Annalisa Quattrocchi; Andrea Maugeri; Maria Clara La Rosa; Claudia La Mastra; Laura Sessa; Pasquale Cananzi; Giuseppe Murolo; Alessandro Oteri; Guido Basile; Antonella Agodi Journal: Int J Environ Res Public Health Date: 2019-06-26 Impact factor: 3.390
Authors: Houda Bennani; Ana Mateus; Nicholas Mays; Elizabeth Eastmure; Katharina D C Stärk; Barbara Häsler Journal: Antibiotics (Basel) Date: 2020-01-28
Authors: Maha Mahmoud Alawi; Wail A Tashkandi; Mohamed A Basheikh; Faten M Warshan; Hazem Ahmed Ghobara; Rosemarie B Ramos; Mary Leilani Guiriba; Omar Ayob; Safiah Saad Janah; Anees Ahmad Sindi; Suheib Ali Abdulhamid Ahmed; Salah Dammnan; Esam Ibraheem Azhar; Ali A Rabaan; Salma Alnahdi; Maged Mohammed Bamahakesh Journal: Interdiscip Perspect Infect Dis Date: 2022-04-12
Authors: Zhuoxin Peng; Andrew Hayen; Martyn D Kirk; Sallie Pearson; Allen C Cheng; Bette Liu Journal: BMC Infect Dis Date: 2020-04-25 Impact factor: 3.090
Authors: Elizabeth D Hermsen; Erina L MacGeorge; May-Lynn Andresen; Laurie M Myers; Christian J Lillis; Bernard M Rosof Journal: Adv Ther Date: 2020-01-17 Impact factor: 3.845
Authors: Jean Carlet; Vincent Jarlier; Jacques Acar; Olivier Debaere; Patrick Dehaumont; Bruno Grandbastien; Pierre Le Coz; Gerard Lina; Yves Pean; Claude Rambaud; France Roblot; Jérôme Salomon; Benoit Schlemmer; Pierre Tattevin; Benoit Vallet Journal: Open Forum Infect Dis Date: 2020-11-06 Impact factor: 3.835